Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan spots hidden cancer spread before surgery

NCT ID NCT06794372

Diagnosis Sponsor: John O. Prior Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether a special PET/CT scan using [68Ga]Ga-FAPI-46 can detect early lymph node metastases in people with head and neck squamous cell carcinoma. The scan targets cancer-associated fibroblasts, which help create a welcoming environment for cancer to spread. Researchers will compare the scan results with standard imaging and with the actual lymph nodes removed during surgery to see if it can identify at-risk nodes before they become full metastases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[68Ga]Ga-FAPI-46 (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this imaging method could help doctors detect lymph node metastases earlier and more accurately, leading to better treatment decisions for head and neck cancer patients.
What could go wrong
This is a small early-phase trial with only 20 participants, so results may not apply to everyone. The imaging technique is still experimental and may not prove better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years old * Karnofsky index ≥80% * Patients with operable head and neck cancer presenting histologically proven HNSCC (including Oral Cavity Cancer, Pharyngeal Cancer, Laryngeal Cancer) * Patients with at least one nodal metastasis * Patients scheduled for neck dissection * SOC imaging (MRI, ceCT and 18F-FDG-PET/CT) performed as pre-surgery exams * Written informed consent obtained Exclusion Criteria: * Known pregnancy or ongoing breast feeding * Claustrophobia * Severe renal insufficiency (GFR\<30 mL/min/1,73 m2) * Liver enzymes (ALAT, ASAT)\>5 times the standard upper limit * Bilirubin\>3 times the standard upper limit * Hemoglobin\<8 g/dL * Absolute neutrophil count\<1000/mm3 * Platelets\<75000/µL * insufficient knowledge of project language, inability to give consent or to follow trial-associated procedures * the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma HNSCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck squamous cell carcinoma HNSCC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre hospitalier universitaire vaudois

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.